# OnCo record selinexor (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/selinexor/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "selinexor" ;
  schema:name "Selinexor"@en ;
  schema:description "Selinexor is a first-in-class pill that traps tumour-suppressor proteins inside the nucleus; approved in myeloma, it failed its endometrial cancer test in 2026."@en ;
  schema:url <https://onco.cc/drugs/selinexor/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Selinexor> ;
  owl:sameAs <http://www.wikidata.org/entity/Q27256082> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Selinexor> ;
  onco:status "approved" ;
  onco:modality "Small-molecule XPO1 (nuclear export) inhibitor" ;
  schema:alternateName "Xpovio" ;
  onco:approval "US 2019: Relapsed/refractory multiple myeloma (≥4 lines) with dexamethasone", "US 2020: Relapsed/refractory DLBCL; myeloma with bortezomib after ≥1 line", "EU 2021: EU brand Nexpovio" ;
  onco:acceleratedApproval "US 2019-07-03: In combination with dexamethasone for adults with relapsed/refractory multiple myeloma after at least 4 prior therapies and refractory to at least 2 proteasome inhibitors, 2 immunomodulatory agents, and an anti-CD38 monoclonal antibody", "US 2020-06-22: Treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma (FL), after at least 2 lines of systemic therapy." ;
  onco:acceleratedApprovalConfirmed "US 2020-12-18: In combination with dexamethasone for adults with relapsed/refractory multiple myeloma after at least 4 prior therapies and refractory to at least 2 proteasome inhibitors, 2 immunomodulatory agents, and an anti-CD38 monoclonal antibody" ;
  onco:cancers <https://onco.cc/cancers/endometrial/>, <https://onco.cc/cancers/multiple-myeloma/>, <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/myeloma-relapsed-refractory/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/tp53/> ;
  onco:companies <https://onco.cc/companies/karyopharm/>, <https://onco.cc/companies/antengene/> ;
  onco:trials <https://onco.cc/trials/xport-ec-042/>, <https://onco.cc/trials/nct04442022/>, <https://onco.cc/trials/nct06158841/>, <https://onco.cc/trials/nct02227251/>, <https://onco.cc/trials/nct02343042/>, <https://onco.cc/trials/nct04414475/>, <https://onco.cc/trials/nct04782687/>, <https://onco.cc/trials/nct04562389/> .